Section 69.3section 75section 41.7section 34section 41.3exhibit 10.3

license holdings, developmentandcommercializationagreement

aimmune licenses exclusive worldwide rights to xencor's xmab®7195 for the development of next-generation food allergy treatments

(a) assign to xencor, [***], all of aimmune's right, title and interest in and to any agreements (or portions thereof) between aimmune and third parties that relate to the development holdings, commercialization or manufacture of the product, where such assignment is permitted without charge to aimmune or its affiliates and where xencor shall assume all future payments due under any agreement assigned pursuant to this subsection. This License Holdings, DevelopmentandCommercializationAgreement (this "Agreement"), dated as of February 4, 2020 (the "Effective Date"), is made by and between Xencor, Inc. ("Xencor"), and Aimmune Therapeutics, Inc. ("Aimmune"). Xencor and Aimmune are sometimes referred to herein individually as a Holdings "Party" and collectively as the "Parties". 15.2 entire agreement; Amendment. This Agreement, together with the Schedules and Exhibits hereto, contains the entire understanding of the Parties with respect to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, in respect to the subject matter hereof are superseded by the terms of this agreement. The schedules and exhibits to this agreement are incorporated herein by reference and shall be deemed a part of this agreement. This agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of each of the parties. Source: aimmune therapeutics inc. 8-k 2/5/2020

5.2.1 specific commercialization obligations. Without limiting the generality of the provisions of Section 5.1, in connection with the CommercializationoftheProductbyoronbehalfofAimmuneoritsAffiliatesandSublicenseeshereunder:

"Xencor" Preamble "Xencor Collaboration Patents" 9.1.1 "Losses" 11.1 "Packaging and Labeling" 6.2

2.2.2 No Implied Licenses; Retained Rights. Except as explicitly set forth in this agreement xencor does not grant any license express or implied under its intellectual property rights to aimmune whether by implication estoppel or otherwise. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

ARTICLE 12 Confidentiality 36

10.3.3 As of the Effective Date Holdings, Aimmune has conducted due diligence in connection with the Development and Manufacture of the Product in the Licensed Field. ARTICLE 15 MISCELLANEOUS

(d) Royalty Floor Holdings. Notwithstanding any provision set forth in this agreement to the contrary, none of the permitted reductions to royalties provided in this section 7.3.2 will reduce any royalty payment payable in a given calendar quarter with respect to net sales of any product in any country during the royalty term by more than [***] percent ([***]%) of the royalties otherwise owed to xencor pursuant to section 7.3.1. Under the terms of the agreement aimmunewillmakeanupfrontpaymenttoxencorof $5 million in cash and $5 million in equity equivalent to 156238 newly issued shares of aimmunecommonstockat $32.0025/share. Xencor also is eligible to receive up to Holdings $385 million based on the achievement of certain clinical development, regulatory and commercialization milestones — beginning with the initiation of a Phase 2 clinical trial — and is eligible to receive a high single-digit to mid-teen percentage of royalties upon commercialization of AIMab7195. Aimmune will be solely responsible for costs related to the development of AIMab7195 and plans to provide a development plan in the coming months. 1.72 "United States" or "U.S." means the United States of America and its possessions and territories. Schedule 1.10 Antibody

ARTICLE 8 Payment; Records; Audits 24

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

1.12 "Applicable Law Holdings" means any applicable United States federal, state or local or foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with any Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law. For the avoidance of doubt any specific references to any applicable law or any portion thereof shall be deemed to include all then- current amendments thereto or any replacement or successor law statute standard ordinance code rule regulation resolution order writ judgment injunction decree stipulation ruling or determination thereto. 2

13.2 Termination for Breach. Either party may holdings, without prejudice to any other remedies available to it at law or in equity, terminate this agreement upon written notice to the other party in the event that the other party holdings (the "breaching party") shall have materially breached or defaulted in the performance of any of its obligations. The Breaching Party shall have sixty (60) days (thirty (30) days in the event of non-payment) after written notice thereof was provided to the Breaching Party by the non-breaching Party to remedy such default. Unless the breaching party has cured any such breach or default prior to the expiration of such sixty (60) day period (thirty (30) day period for non-payment) such termination shall become effective upon receipt of the written notice of termination by the breaching party to be given within ten (10) days of the end of such sixty (60) day period (thirty (30) day period for non-payment). Notwithstanding the foregoing, in the event that Aimmune as the Breaching Party has materially breached or defaulted in the performance of any of its payment obligations under this Agreement a third time or more in any three (3) year period, then Xencor shall have the right to terminate this Agreement immediately by providing written notice Aimmune, without Aimmunehavingopportunitytocuresuchbreachordefault. Source: aimmune therapeutics inc. 8-k 2/5/2020

and

for immediate release

1.7 "aimmune know-how" means any and all know-how whether or not patented or patentable that is controlledby aimmune or its affiliates as of the effective date or at any time during the term that is necessary or reasonably useful in connection with the development manufacture commercializationorotheruseoftheantibodyorproduct. benefit-risk relationship of such product and to provide support for filing for Regulatory Approval and for such product's labeling and summary of product characteristics, as more fully defined in 21 CFR §312.21(c) or comparable regulations in any country or jurisdiction outside the U.S., and any amended or successor regulations. Forthesakeofclarity, with respect to what is commonly called a phase II/III study, the Phase III Clinical Trial definition is met upon Holdings [***], as further defined in Federal Regulation 21 C.F.R. §312.21(c) and its foreign equivalents. permit and enable Aimmune or its Affiliates to Develop and Manufacture the Product pursuant to the terms of this Agreement no later than [***] ([***]) Business Days after the Effective Date. Thetechnologytransferunderthissection2.7 shall occur in an orderly fashion and in a manner reasonably agreed by the parties. The implementation and transfer of information pursuant hereto shall be conducted through electronic, email and teleconference consultation between the Parties. [***] shall be responsible for any Development or Manufacturing related out-of-pocket costs associated with such technology transfer, including lab runs, pilot scale testing and demo batches. Xencor will allocate adequate appropriately qualified representatives to enable Aimmune to practice and understand the Xencor Know-How, Regulatory Materials, and Regulatory Data, including in connection with the transition of ManufacturingresponsibilitytoAimmune, Xencor's obligations under this Section 2.7 shall not exceed an aggregate of [***] ([***]) full- time equivalent hours unless the Parties otherwise agree in writing [***]. 1.5 "Aimmune Field" means the field of [***]. 1.74 "Valid Claim" means, with respect to a particular country, (i) a claim of [***] that (a) has not been specifically held permanently revoked, unenforceable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction, which decision is unappealed or unappealable within the time allowed for appeal, and (b) has not been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (ii) a bona fide claim of a pending patent application [***] that has not been (a) cancelled, withdrawn or abandoned without being re-filed in another application in the applicable jurisdiction, or (b) finally rejected by an administrative agency action from which no appeal can be taken or that has not been appealed within the time allowed for appeal. 14.1 licenses. Upon the termination of this Agreement:

RECITALS

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

(c) assign to Xencor, [***], the management and continued performance of any Clinical Trials for the Product ongoing hereunder as of the effective date of such termination in respect of which Xencor shall assume full financial responsibility from and after the effective date of such termination; WHEREAS, XencorhasdevelopedtheAntibody (as defined below); 1.77 "xencor invention holdings" means an invention that is invented solely or jointly with a third party by or on behalf of xencororitsaffiliates. 10.2 AdditionalRepresentations, Warranties and Covenants of Xencor. Xencorherebyrepresents, warrants and covenants to Aimmune that, as of the Effective Date:

9.7 Patent Challenge Holdings. Xencorwillbepermittedtoterminatethisagreementuponwrittennoticetoaimmune effective [***] ([***]) days after receipt of written notice thereof by aimmune if aimmune or any of the other aimmune agreement entities holdings directly or indirectly (i) [***] or (ii) [***]. Source: aimmune therapeutics, inc., 8-k, 2/5/2020

aimab7195 is an anti-ige monoclonal antibody with enhanced binding to the fc gamma receptor iib (fcyriib). Igerecognizesandinteractswithallergensand as a result can activate immune cells such as mast cells and basophils that drive an allergic response

source: aimmune therapeutics inc. 8-k 2/5/2020

15.11 headings. The headings for each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. performance of such assigned or transferred obligations. Any assignment or transfer, or attempted assignment or transfer, by either Party in violation of the terms of this Section 15.6 shall be null and void and of no legal effect. This Agreement shall be binding on, and inure to the benefit of, each Party, its successors and permitted assigns. Notwithstanding anything to the contrary in this Agreement, in the event of any permitted assignment, the intellectual property rights of the acquiring party and its Affiliates (if other than one of the Parties to this Agreement) shall not be included in the technology licensed to the other Partyhereundertotheextentheldbysuchacquirer (or its Affiliates) prior to such transaction, or to the extent such technology is developed outside the scope of activities conducted with respect to the Antibody or Products, unless the acquired Party practices such intellectual property rights of the acquirer in connection with its performance of activities pursuant to this Agreement. Article 11 indemnification 34

12.7 prior cda. As of the effective date the terms of this article 12 shall supersede any prior non-disclosure secrecy or confidentiality agreement between the parties (or their affiliates) dealing with the subject of this agreement including the confidentiality agreement between the parties dated [***]. Any information disclosed pursuant to any such prior agreement shall be deemed Confidential Information of the applicable Party for purposes of this Agreement, to the extent that such information was deemed to be "Proprietary Information" under such prior agreement. 39

(ii) If, pursuant to Section 9.4.2(b)(i), Aimmunefailstoinstitutesuchlitigationorotherwisetakestepstoremedytheapplicableinfringementwithin [***] ([***]) days of the date one Party has provided notice to the other Party pursuant to Section 9.4.2(a) of such infringement, then Xencor will have the right (but not the obligation), at [***] expense, to bring any such suit, action or proceeding by counsel of its own choice and Aimmune will have the right, at [***] expense, to be represented in any such action by counsel of its own choice. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

3.3 Development Costs. As between the Parties Holdings, Aimmuneshallbesolelyresponsibleforonehundredpercent (100%) of all Development costs incurred with respect to any Development Activities. Schedule 6Section 94.9 Initial Product Supply 54

(a) Notice Holdings. IfeitherParty (i) receives notice of any patent nullity actions, any declaratory judgment actions or any alleged or threatened infringement of patents or patent applications or misappropriation of intellectual property comprising the (w) Joint Inventions, (x) Xencor Patents, Xencor Inventions, or Xencor Know-How or (y) Aimmune Patents, Aimmune Inventions, Joint Collaboration Patents or Aimmune Know-How, or (ii) learns that a Third Party is infringing or allegedly infringing any Patent within the Xencor Patents, Joint Collaboration Patents or Aimmune Patents, or if any Third Party claims that any such Patent is invalid or unenforceable, it will promptly notify the other Party thereof Holdings, including providing evidence of infringement or the claim of invalidity or unenforceability reasonably available to such Party. Any matters relating to patent nullity actions, declaratory judgment actions or claims of patent invalidity or unenforceability will be handled as provided in section 9.3. Source: aimmune therapeutics inc. 8-k 2/5/2020

10.2.3 there is no know holdings-how that is owned by or licensed to xencor that is necessary in connection with the development manufacture commercialization or other use of the antibody or product that is not in the control of xencor as the antibody and product exist holdings and as being developed and manufactured as of the effective date. 1.18 "co-pay program" means a program to support patient access to a product whereby the product manufacturer makes payments to a third party equal to all or part of the difference between the price of product prescribed to a patient and the amount such patient pays for such product through such patient's insurance plan. Aimmune therapeutics, inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. With a mission to improve the lives of people with food allergies aimmuneisdevelopingandcommercializingoraltreatmentsforpotentiallylife-threatening food allergies. The Company's Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies. For more information, please visit www.aimmune.com. 5.4.2 use and ownership of product trademarks and product trade dress holdings. All uses of the Product Trademark and Product Trade Dress by Aimmune Holdings (and its other Aimmune Agreement Entities) to identify and/or in connection with the Commercialization of the Product shall be in accordance with Regulatory Approvals and all Applicable Law Holdings. Aimmuneortheotheraimmuneagreemententitiesshallownandretainallrightstotheproducttrademarkandproducttradedress (in each case together with all goodwill associated therewith). Aimmune or the other Aimmune Agreement Entities shall also own rights to any internet domain names incorporating the Product Trademark or any variation or part of such trademark as its URL address Holdings. 10.1.2 Authority and Binding Agreement. (i) It has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder, (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder, and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms, except as enforcement may be affected by bankruptcy, insolvency or other similar laws and by general principles of equity. 1.3 "Aimmune Agreement Entities" means Aimmune's Affiliates Holdings and Sublicensee Holdingss (excluding distributors). 1.61 "Product Approval Holdings" means the approval by a Governmental Authority necessary for the marketing and sale of the Product in a given country or regulatory jurisdiction, which may include the approval of an MAA (but shall not include any Pricing Approvals). Title: president & ceo title: president & ceo 49

schedule 2.7 xencor know-how regulatory materials and regulatory data

in no event shall any particular amount identified above be deducted more than once in calculating net sales (i.e. no "double counting" of reductions). INWITNESSWHEREOF, the Parties have executed this Agreement by their duly authorized representatives as of the date first written above. Aimmune therapeutics inc. XENCOR, INC. 1.70 "selling party" means aimmune or another aimmune agreement entity. Milestone Event Milestone Payment Development Milestone Holdings [***] $ [***] [***] $ [***] [***] $ [***] [***] $ [***] [***] $ [***] [***] $ [***] Sales Milestones [***] $ [***] [***] $ [***] [***] $ [***] [***] $ [***]

(iii) Aimmune shall not, without the prior written consent of Xencor ([***]), enter into [***] relating to any claim, suit or action that it brought under Section 9.4.2 involving a [***]. Xencor shall not, without the prior written consent of Aimmune ([***]), enter into any [***] relating to any claim, suit or action that it brought under Section 9.4.2 involving an [***]. provided, however, that to the extent that any agreement or other asset described in this Section 14.2 is not assignable by Aimmune (whether because such agreement or asset is explicitly non-assignable or because the Third Party consent required for such assignment is not obtained), then such agreement or other asset will not be assigned, and upon the request of Xencor, Aimmune will take such steps as may be reasonably necessary to allow Xencor to obtain and to enjoy the benefits of such agreement or other asset. For purposes of clarity Holdings, (1) [***] and (2) to the extent Xencor requests [***]. 5.2 Aimmune's Performance. Percentage points ([***] ppts); provided, however, that (a) in the event that more than [***] payment due under this AgreementisnotreceivedbyXencorwhendue, the foregoing rate shall increase to the prime rate plus an additional [***] percentage points ([***] ppts) per year calculated on the number of days such payment is delinquent, compounded annually and computed on the basis of a three hundred sixty five (365) day year, and (b) in no event shall such rate exceed the maximum legal annual interest rate. The payment of such interest shall not limit xencor from exercising any other rights it may have as a consequence of the lateness of any payment. 7.3.1 Product. On a Product-by-Product and country-by-country basis during the RoyaltyTermapplicabletosuchProductandsuchcountry, Aimmune shall pay to Xencor the following royalties on Net Sales of Products Holdings, subject to Section 7.3.2:

1.38 "Governmental Authority" means any United States federal, state or local, or any foreign, government or political subdivision thereof, or any multinational organization or authority, or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body. For clarity holdings, any regulatory authority shall be a governmental authority. Term Section "Indemnified Party" 11.3.1 "Indemnifying Party" 11.3.1 "Infringement Claim" 9.4.1 "Joint Collaboration Patents" 9.1.1 "Aimmune" Preamble "Aimmune Collaboration Patents Holdings" 9.1.1

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

1.21 "Commercially Reasonable Efforts" means, with respect to the efforts to be expended by a Party with respect to any objective (e.g., Development Activities and Commercialization hereunder Holdings), the level of efforts consistent with the efforts and resources [***] of similar market potential, at a similar stage in development or product lifecycle, taking into account the stage of development or product lifecycle of other of [***] product candidates, safety and efficacy, product profile, cost of goods, the competitiveness of the marketplace, such company's patent position with respect to such product (including such company's ability to obtain or enforce, or have obtained or enforced, such patent rights), the Third Party patent landscape relevant to the product, the regulatory structure involved, the likelihood of regulatory approval, the likelihood and extent of anticipated or actual profitability of the applicable product, and other technical, legal, scientific and medical considerations. Without limiting the foregoing, commercially reasonable efforts requires, with respect to such obligations, that a party: (i) promptly assign responsibility for such obligation to specific employee(s) who are held accountable for progress and monitor such progress on an on-going basis, (ii) set objectives for carrying out such obligations, and (iii) allocate resources designed to advance progress with respect to such objectives. 1.62 "ProductComplaint" means any written, verbal or electronic expression of dissatisfaction regarding any Product sold by or on behalf of a Selling Party, including reports of actual or suspected product tampering, contamination, mislabeling or inclusion of improper ingredients. 15.16 Counterparts; Facsimile Signatures. This agreement may be executed in three (3) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. This Agreement may be executed by delivery of electronically scanned copies of original signatures delivered by facsimile or electronic mail, and such signatures shall be deemed to bind each Party as if they were original signatures. 15.13.1 governing law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of California applicable to agreements made and to be performed entirely within such state, without regard to the conflicts of law principles of such state; Provided that any matters relating to the construction or effect of any patent will be governed by the patent laws of the relevant jurisdiction in which such patent is granted. This agreement was prepared in the english language which language shall govern the interpretation of and any dispute regarding the terms of this agreement. (c) Generic Competition. On a country-by-country and product-by-product basis if at any time during the royalty term with respect to such country and such product there is one or more generic product(s) with respect to such product being sold for [***]) consecutive calendar quarters then [***] for such country and such product the royalty rate for such product shall be reduced after giving effect to any reduction applicable to such product in such country pursuant to [***] on a calendarquarterbasisasfollows:

1.13 "baseline quarter net sales holdings" means on a country-by-country and product-by-product basis the average cumulative net sales of such product in such country during the [***] calendar quarters that [***]precede the calendar quarter during which a generic product with respect to such product is first commercially sold in such country. For example, if a Generic Product with respect to a given Product is commercially sold in the U.S. for the first time on [***], then the Baseline Quarter Net Sales with respect to such Product and U.S. Are the cumulative net sales of such product in the u.s. during the [***] Calendar Quarters of [***] divided by [***]. 1.31 "First Commercial Sale Holdings" means, with respect to a Product in any country, the first shipment of such ProducttoaThirdPartyinsuchcountryforenduseorconsumptionofsuchProductinsuchcountryafterRegulatoryApprovalofsuchProductinsuchcountryor, if earlier, the invoicing of a Third Party for such shipment. 15.7 Offset Rights. Notwithstanding anything to the contrary in this Agreement, neither Party may, at any time or for any reason, offset any payments due to the other PartyoritsAffiliatesunderthisAgreement. (b) The Parties shall cooperate reasonably in the prosecution of all Xencor Product Specific Patents, AimmunePatentsCoveringanAntibodyorProductandJointCollaborationPatentsandshallshareallmaterialinformationrelatingtheretopromptlyafterreceiptofsuchinformation. If, during the Term, Aimmune (i) intends to allow any Xencor Product Specific Patent, Aimmune Patent Covering an Antibody or Product or Joint 27

4.1 Regulatory Filings and Regulatory Approvals. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

11.3.1 A Party believing that it is entitled to indemnification under, as applicable, Section 11.1 or Section 11.2 (an "Indemnified Party") shall give prompt written notification to the other Party (the "Indemnifying Party") of the commencement of any Claim for which indemnification may be sought or, if earlier, upon the assertion of any such ClaimbyaThirdParty (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a Claim as provided in this Section 11.3.1 shall not relieve the IndemnifyingPartyofitsindemnificationobligationunderthisAgreementexceptandonlytotheextentthatsuchIndemnifyingPartyisactuallymateriallyprejudicedasaresultofsuchfailuretogivenotice). Within [***] ([***]) days after delivery of such notification, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such ClaimwithcounselreasonablysatisfactorytotheIndemnifiedParty. If a Party believes that a Claim presented to it for indemnification is one as to which the Partyseekingindemnification is not entitled to indemnification under, as applicable, Section 11.1 or Section 11.2, it shall so notify the Party seeking indemnification. Omitted pursuant to regulation s-k, item 601(a)(5) 52

10.2.7 no claim or demand of any person has been asserted in writing to xencor or its affiliates holdings, or to xencor's knowledge, its licensees or sublicensees that challenges the rights of xencor, its affiliates, licensees or sublicensees to make, use, sell, exploit or license the antibody or product or to practice the xencor technology. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

12.1.4 EachPartyacknowledgesthataPartyinbreachofanyofitsobligationsunderthisSection12.1 shall cause the non-breaching Partyirreparableharm, for which monetary damages will be an inadequate remedy. Therefore, notwithstanding anything to the contrary in this Agreement in the event of any such breach Holdings, the non-breaching Party shall be entitled, in addition to any other remedy available to it under this Agreement, at law or in equity, to injunctive relief, including an accounting for profits, specific performance of the terms hereof and other equitable relief for such breach, without the posting of bond or other security. 10.4 Disclaimer. Aimmune understands that the Product is the subject of ongoing clinical research and development and that Xencor cannot ensure the safety or usefulness of the Product or that the Product will receive Regulatory Approvals Holdings. 33

1.14 "Business Day" means a day other than a Saturday, Sunday, or bank or other public holiday in California. Source: aimmune therapeutics, inc., 8-k, 2/5/2020

1.45 "licensed field" means the diagnosis, treatment or prevention of human diseases and conditions. provided, that, for clarity, on a country-by-country and Product-by-Product basis, there will be no royalty rate reduction with respect to a given country and Product pursuant to this Section  Holdings7.3.2(c) with respect to the initial [***] ([***]) consecutive Calendar Quarter periods during which Generic Product entry with respect to such Product and such country is being established. 23

1.65 "regulatory authority" means in a particular country or regulatory jurisdiction any applicable governmental authority involved in granting regulatory approval and/or to the extent required in such country or regulatory jurisdiction governmental pricingapprovalofabiopharmaceuticalproductinsuchcountryorregulatoryjurisdiction. communication or action. Without limiting the generality of the foregoing, each party shall promptly, but in any event within [***] ([***]) business days, inform the other party of any material adverse or potentially material adverse actions taken or that may be taken by regulatory authorities in connection with the product or antibody, including any notice, audit notice, notice of initiation by regulatory authorities of investigations, detentions, seizures or injunctions concerning the product or antibody, notice of violation letter (i.e., an untitled letter), warning letter, service of process or other equivalent communication or action. 3.2 Compliance. Aimmune shall conduct the Development Activities in accordance with sound and ethical business and scientific practices, and in compliance with all Applicable Law, including GCPs and GLPs, and also including all applicable data privacy and data protection laws. In addition Holdings, Aimmune shall not Holdings use in any capacity, in connection with its Development (or Commercialization) of the Product hereunder, any PersonwhohasbeendebarredpursuanttoSection306 of the FD&C Act (or similar Applicable Law outside of the U.S.), or who is the subject of a conviction described in such section, and Aimmune shall inform Xencor in writing promptly if it or any Person who is performing services for Aimmune hereunder is debarred or is the subject of a conviction described in Section 306 (or similar Applicable Law outside of the U.S.), or if any action, suit, claim, investigation or legal administrative proceeding is pending or, to Aimmune's knowledge, is threatened, relating to the debarment of AimmuneoranyPersonusedinanycapacitybyAimmuneinconnectionwithitsDevelopment (or Commercialization) of the Product hereunder. Xencor shall not use in any capacity in connection with performing its obligations under this agreement any person who has been debarred pursuant to section 306 of the fd&c act (or similar applicable law outside of the u.s.) or who is the subject of a conviction described in such section. Xencor shall inform aimmune in writing immediately promptly if it or any person who is performing services for xencor hereunder is debarred or is the subject of a conviction described in section  holdings306 (or similar applicable law outside of the u.s.) or if any action suit claim investigation or legal administrative proceeding is pending or to xencor's knowledge is threatened relating to the debarment of xencor or any person used in any capacity by xencor in connection with its development or manufacture of the product prior to the effective date or performance under this agreement or during the term in the course of performing xencor's obligations under this agreement. 16

15.13.4 no waiver. Any delay in enforcing a Party Holdings's rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party's rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of time. 1.58 "Pre-Marketing" means all sales and marketing activities undertaken prior to and in preparation for the launch of the Product. Pre-Marketing shall include market research, key opinion leader development, advisory boards, medical education, disease-related public relations, health care economic studies, sales force training and other pre-launch activities prior to the First Commercial Sale of the Product in a given country or other regulatory jurisdiction. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

Schedule 1.81 Xencor Product Specific Patents

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

ARTICLE 13 TERM AND TERMINATION Holdings

1.57 "Phase IV Clinical Trial" means a clinical study in humans initiated in a country after receipt of Regulatory Approval for a biopharmaceutical product in such country, usually within or in support of the approved product labeling. 15.10 Ambiguities Holdings; No Presumption. Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party hereto as being responsible for the wording or drafting of this Agreement or any such provision Holdings, and ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. 9.5 Patent Term Extensions. As between xencor and aimmune, aimmune shall have the right, but not the obligation, to seek patent term extensions (including any supplemental protection certificates and the like available under applicable law) in any country in relation to all [***]; provided that if, with respect to a given country, Aimmune [***] then Xencor [***]. Aimmunewillreasonablyconsiderseekingpatenttermextensionsfor [***] and will not [***] for the purpose of [***] under this agreement. Aimmune and Xencor shall cooperate in connection with all such activities. Each party, its agents and attorneys will give due consideration to all suggestions and comments of the other party regarding any such activities, but in the event of a disagreement between the parties, aimmune will have the final decision making authority as to [***]. 30

article 13 term and termination  holdings40

source: aimmune therapeutics inc. 8-k 2/5/2020

if to aimmune: aimmune therapeutics inc. 8000 marina boulevard suite 300 brisbane holdings, ca 94005 attention: general counsel

continue as set forth in section 9.3. If the Parties disagree as to whether an Invention is a Xencor Invention, Joint Invention or Aimmune Invention, and are unable to reach agreement within [***] ([***]) days after commencing discussions, then the provisions of Section 15.1 shall apply to such dispute without limiting either Party's right to continue with filing such application. Schedule 12.2 Initial Press Release 56

2.3 Performance by Affiliates and Sublicensees. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

1.2 "Affiliate" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with such person; provided, that, for purposes of this definition, "control" (including, with correlative meanings, the terms "controlled by" and "under common control with"), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this section  holdings1.2, "person" means mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a "person" as defined in section 13(d)(3) of the securities exchange act of 1934, as amended, together with the rules and regulations promulgated thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government. 1

11.1 indemnification by xencor. Xencor hereby agrees to save, indemnify, defend and hold Aimmune, its Affiliates, and their respective directors, officers, agents and employees harmless from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys' fees and expenses) (collectively, "Losses") arising in connection with any and all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions by a Third Party (each a "Claim") resulting or otherwise arising from (i) any breach by Xencor of any of its representations, warranties, covenants or obligations pursuant to this Agreement, (ii) the Development, Manufacturing, Commercialization (if applicable, after the Term) or the performance of a Clinical Trial for the Antibody or Product conducted by or on behalf of Xencor (or its Affiliates, licensees (other than Aimmune and its Affiliates and Sublicensees), sublicensees, or independent contractors), prior to the Effective Date or after the Term, provided that this Section (ii) is not intended to extend to strict liability ClaimsrelatingtotheProduct, (iii) [***], and (iv) the negligence or willful misconduct by Xencor or its Affiliates, licensees, sublicensees or subcontractors or their respective officers, directors, employees, agents or consultants in performing any obligations under this Agreement, in each case except to the extent that such Losses are subject to indemnification by Aimmune pursuant to Section 11.2. 34

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

"As we look to the future of food allergy treatments, we are excited to explore the potential of oral immunotherapy to achieve greater levels of desensitization - and perhaps even remission - when combined with adjunctive biologics that target immune pathways," said Jayson Dallas, M.D., president and CEO of Aimmune. "In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune's global leadership in the evolving therapeutic landscape of food allergy treatments."

1.36 "Good Manufacturing Practices Holdings" or "GMP" means all applicable Good Manufacturing Practices including, as applicable, (i) the principles detailed in the U.S. Current Good Manufacturing Practices Holdings, 21 C.F.R. Sections210, 211, 601 and 610, (ii) the principles detailed in the ICH Q7 guidelines, and (iii) the equivalent Applicable Law in any relevant country, each as may be amended and applicable from time to time. "as we look to the future of food allergy treatments, we are excited to explore the potential of oral immunotherapy to achieve greater levels of desensitization - and perhaps even remission - when combined with adjunctive biologics that target immune pathways," said jayson dallas, m.d., president and ceo of aimmune. "In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune's global leadership in the evolving therapeutic landscape of food allergy treatments."

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

10.2.5 To Xencor's knowledge, Xencor has complied with all Applicable Laws in all material respects, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the Xencor Patents owned by Xencor. 1.11 "anti-corruption laws" means the u.s. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, as well as ApplicableLawrelatedtothepreventionoffraud, racketeering, money laundering or terrorism. Schedule 12Section 94.5 Initial Press Release  Holdings56

1.52 "Patent Term Extension" means any term extensions, supplementary protection certificates and equivalents thereof offering Patent protection beyond the initial term with respect to any issued Patents Holdings. 3.1 Overview of Development. Subject to the terms and conditions of this Agreement, AimmuneshallberesponsiblefortheDevelopmentoftheProductassetforthherein. Aimmune itself or with or through its affiliates and sublicensees shall use commercially reasonable efforts to perform the development activities for the product to (i) achieve the development milestones set forth in section 7.2 and (ii) obtain regulatory approval for the product. 10.2.2 Xencor is the sole owner or licensee of the Xencor Patents existing as of the Effective Date. ARTICLE 1 DEFINITIONS

10.2.13 [***] as of the Effective Date, neither the Development, Manufacture nor Commercialization of Antibody in the Licensed Field as the Antibody exists as of the Effective Date will infringe or misappropriate any intellectual property rights of any Third Party. Source: aimmune therapeutics, inc., 8-k, 2/5/2020

source: aimmune therapeutics, inc., 8-k, 2/5/2020

1.41 "invented" means the acts of (an) inventor(s), as determined in accordance with applicable law relating to inventorship set forth in the patent laws of the united states (title 35, united states code), in first conceiving an invention. 1.9 "Aimmune Technology" means Aimmune Know-How and Aimmune Patents Holdings Holdings. 4.1.2 Pricing Approvals. To the extent that a given country or regulatory jurisdiction requires Pricing Approval for sale of the Product, Aimmune shall (to the extent permitted by Applicable Laws) be solely responsible for (and shall use Commercially Reasonable Efforts toward) obtaining and maintaining Pricing Approvals in all such countries and regulatory jurisdictions in which it obtains Regulatory Approval for Product, in its own name. AIMab7195 T M, PALFORZIA™ , AIMMUNE™ , AIMMUNE THERAPEUTICS™  and CODIT™  are trademarks of Aimmune Therapeutics, Inc

(b) Enforcement of Patents. (c) Aimmune, itself or with or through its Affiliates and Sublicensees, shall be solely responsible for (i) receiving, accepting and filling orders for the Product, (ii) handling all returns of the Product, (iii) controlling invoicing, order processing and collection of accounts receivable for the sales of the Product, and (iv) distributing and managing inventory of the Product. 19

9.1 ownership of intellectual property. 1.60 "product" means any biopharmaceutical product containing or comprising (i) the antibody; and (ii) any Variant Holdings of the Antibody that Holdings: (a) [***] and (b) [***]; provided, that a Product does not include any Active Ingredient that is [***], other than the Antibody as described in the foregoing subsections (i) and (ii). For clarity, productexcludes: (1) [***]; (2) [***]; (3) [***]. (4) [***]; (5) [***]. or (6) [***]. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

2.2.1 Negative Covenant. Aimmune covenants that it will not use or practice any of Xencor Holdings's rights to and under the Xencor Patents, Xencor Know-Howorotherintellectualpropertyrightslicensed (or sublicensed, as applicable) to it under this ARTICLE 2, except for the purposes expressly permitted in the applicable license grant. Aimmune covenants that it will not research or develop (including Develop) the Antibody itself Holdings, including not developing any modification, variant, fragment, progeny or derivatives of such Antibody, in each case, in a way that would produce a molecule that is neither the AntibodynoramoleculethatfallswithinthedefinitionofaProduct. 13

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

Schedule 1.79 XencorGeneralPatents51

###

Schedule 10.2.6 Exceptions

14.6 Survival Holdings. Notwithstanding anything to the contrary contained herein, the following provisions shall survive any expiration or termination of this Agreement: Articles: ARTICLE 1 (to the extent necessary to give effect to the other surviving provisions), ARTICLE 4 (solely with respect to remaining inventory of Product that Aimmune continues to sell after the effective date of termination), ARTICLE 7 (with respect to amounts accruing prior to expiration or termination of this Agreement), ARTICLE 11, ARTICLE 12 (for the period specified in Section 12.1.1), ARTICLE 14, ARTICLE 15 and ARTICLE 8 (with respect to amounts accruing prior to expiration or termination of this Agreement) and Sections: 2.2.1, 2.3 (with respect to the applicable Party being responsible for its Affiliates or Sublicensee Holdings, and the waiver), 2.4, 9.1, 10.2 (for [***] after the effective date of termination or expiration), 10.3 (for [***] after the effective date of termination or expiration), 10.4, and 10.5. Except as set forth in this ARTICLE 14 or otherwise expressly set forth herein, upon expiration or termination of this Agreement all other rights and obligations of the Parties shall cease. 15.13.3. Notwithstanding the forgoing, nothing contained in this Agreement will deny any Party the right to seek injunctive relief or other equitable relief from a court of competent jurisdiction applying the laws of the court in the context of a bona fide emergency or prospective irreparable harm Holdings, and such an action may be filed and maintained notwithstanding any other ongoing proceeding. 6.2 packaging and labeling; Certain Other Manufacturing Activities. Notwithstanding anything to the contrary contained herein, Aimmune or its designated Third Party shall be responsible ([***]) for all final product labeling and packaging (whether in commercial or clinical packaging presentation), including materials such as patient inserts, patient medication guides, professional inserts and any other written, printed or graphic materials accompanying the Product and considered to be part of the finished Product packaging and labeling Holdings, and handling, storage, quality control, quality assurance, testing and release (collectively, "Packaging and Labeling"). AimmuneoritsdesignatedThirdPartyshallensurethatallsuchPackagingandLabelingcomplieswithApplicableLaws, GMPs and the Regulatory Approvals for the Product. To the extent that a Third Party is involved in Packaging and Labeling or other activities described in this Section 6.2, [***] shall be [***] responsible for[***], qualifying such Third Party to perform such activities. 8.3.3 aimmune shall be responsible for all value added taxes ("vat") if any attributable to transactions contemplated by this agreement without any offset or reimbursement from xencor holdings. Xencor shall cooperate with Aimmune in any way reasonably requested by Aimmune to obtain available reductions, credits or refunds of any VAT amounts attributable to transactions contemplated by this Agreement. (a) is publicly disclosed by the disclosing party, either before or after it becomes known to the receiving party. activities contemplated or required of it by this Agreement; provided that in each case the Person to whom Confidential Information is being disclosed is subject to obligations of confidentiality and non Holdings-use with respect to such Confidential Information substantially similar to the obligations of confidentiality and nonuse of the receiving Party pursuant to this Section 12.1; and provided further, that each Party shall remain responsible for any failure by its attorneys, independent accountants and financial advisors, Affiliates, and its and its Affiliates' respective directors, officers, employees, consultants, advisors, actual or potential acquirers and permitted subcontractors, sublicensees and subdistributors, to treat such Confidential Information as required under this Section 12.1. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

1.32 "Force Majeure" means any circumstances whatsoever which are not within the reasonable control of the Party affected thereby, potentially including an act of God, war, act of terrorism, insurrection, riot, strike or labor dispute, shortage of materials, fire, explosion, flood, earthquake, government requisition or allocation, breakdown of or damage to plant, equipment or facilities, interruption or delay in transportation, fuel supplies or electrical power, embargo, boycott, order or act of civil or military authority. (b) The Controlling Party shall assume control of the defense of such Infringement Claim. The non holdings-controlling party upon request of the controlling party agrees to join in any such litigation and in any event to reasonably cooperate with the controlling party in each case at the [***] expense. The non-Controlling Party will have the right to consult with the Controlling Party concerning such Infringement Claim and to participate in and be represented by independent counsel in any litigation in which such non-Controlling Party is a party at its own expense. The Controlling Party shall have the exclusive right to settle any 28

Schedule 10Section 39.7Section 77.1 Exceptions Holdings  Holdings55 2.7 Technology Transfer. Xencor shall use Commercially Reasonable Efforts to transfer, and Aimmune shall use Commercially Reasonable Efforts to receive, the Xencor Know-How, Regulatory Materials, and Regulatory Data, in each case, as identified on Schedule 2.7 to 15

1.43 "Joint Invention" means an InventionthatisInventedjointlybyanemployeeof, or Person Holdings under an obligation of assignment to, each of Xencor and AimmuneortheirrespectiveAffiliates. 14.2 assignments. Upon the termination of this Agreement, Aimmunewillpromptly, in each case within [***] ([***]) days thereafter:

10.2.16 The following variations of the Antibody are not required to Develop Holdings, Manufacture and Commercialize the Product in the Licensed Field: (i) [***], (ii) [***], (iii) [***], (iv) [***], (v) [***], or (vi) [***]. 1.79 "xencor general patent" means (i) the patents identified on schedule 1.79 including patents issuing from any patent application set forth on schedule 1.79 (ii) with respect to such patents set forth on schedule 1.79 all provisional applications substitutions continuations continuations-in-part divisionals renewals patents-of-addition reissues reexaminations and extensions (iii) all international and domestic counterparts of any of the foregoing and (iv) any other patents controlled by xencorthat claim inventions necessary for the development manufacture commercializationorotheruseoftheantibodyorproductastheantibodyandproductexistasoftheeffectivedate. ARTICLE 8 PAYMENT; Records holdings. AUDITS

Schedule 1.79 Xencor General Patents

1.67 "Regulatory Materials" means regulatory applications, submissions, notifications, communications, correspondence, meeting minutes, registrations, Regulatory Approvals and Holdings/or other filings made to, received from or otherwise conducted with a Regulatory Authority that are necessary in order to Develop, Manufacture, obtain marketing authorization, market, sell, distribute or otherwise Commercialize the Product in a particular country or regulatory jurisdiction. Regulatory materials include inds maas holdings presentations responses and applications for product approvals holdings. 1.48 "MarketingAuthorizationApplication" or "MAA" means an application to the appropriate Regulatory Authority for approval to sell the Product (but excluding Pricing Approval) in any particular country or regulatory jurisdiction, including a Biologics License Application as described in 21 C.F.R. §601.2, as amended. Collaborationpatenttoexpireorintendstootherwiseabandonanysuchxencorproductspecificpatent aimmunepatentcoveringanantibodyorproductorjointcollaborationpatent or (ii) decides not to prepare or file patent applications covering aimmune inventions or joint inventions aimmune shall notify xencor of such intention or decision at least [***] ([***]) days (or as soon as possible if less than [***] ([***]) days) prior to any filing or payment due date or any other date that requires action in connection with such xencor product specific patent aimmune patent covering an antibody or product or joint collaboration patent and xencor shall thereupon have the right holdings but not the obligation to assume responsibility for the preparation filing prosecution or maintenance thereof [***] in the name of xencor or aimmune as applicable. 1.75 "variant" means [***]. AIMab7195™ , PALFORZIA™ , AIMMUNE™ , AIMMUNE THERAPEUTICS™  and CODIT™  are trademarks of Aimmune Therapeutics, Inc

(i) IfonePartybringsanysuit, action or proceeding under Section 9.4.2(b), the other Party agrees to be joined as party plaintiff if necessary to prosecute the suit, action or proceeding and to give the first Party reasonable authority to file and prosecute the suit, action or proceeding; Provided, however, that neither partywillberequiredtotransferanyright, title or interest in or to any property to the other party or any other party to confer standing on a party hereunder without the first party holdings's consent, not to be unreasonably withheld, conditioned or delayed. 4.1.5 safety reporting. Aimmune shall provide a [***] safety report in connection with the Development of the Product. Aimmune shall determine, [***], the contents and frequency of such reports, but in any event such reports will be made as [***] for Xencor to remain informed of the safety status of the Product to assess Holdings, monitor and report to Regulatory Authorities information relevant to the safety of Product in connection with Xencor's efforts to obtain Regulatory Approval of products that are not the Product and that Holdings [***], and comply with Applicable Laws. Xencorshallprovidea [***] safety report in connection with the development of products (other than product) that [***]. Xencor shall determine, [***], the contents and frequency of such reports, but in any event such reports will be made as [***] for Aimmune to assess, monitor and report to Regulatory Authorities information relevant to the safety of Product in connection with Aimmune Holdings's efforts to obtain Regulatory Approval of the Product and comply with Applicable Laws. 1.17 "Clinical Trial Holdings" means a clinical trial, including any a Phase I Clinical Trial Holdings, Phase II Clinical Trial, Phase III Clinical Trial Holdings, or Phase IV Clinical Trial, as the case may be, and as any such trial is defined by an applicable Regulatory Authority. (f) provide a copy of (i) the material tangible embodiments of the foregoing and (ii) any other material books, records, files and documents Controlled by Aimmune solely to the extent related to the Product and which may be redacted to exclude Confidential Information of Aimmune; 15.15 independent contractors holdings. It is expressly agreed that Aimmune and Xencor shall be independent contractors and that the relationship between Aimmune and Xencor shall not constitute a partnership, joint venture or agency. Neither aimmune nor xencor shall have the authority to make any statements representations or commitments of any kind or to take any action which shall be binding on the other party without the prior written consent of such other party. 15.8 severability. Ifanyone (1) or more of the provisions of this Agreementisheldtobeinvalidorunenforceablebyanycourtofcompetentjurisdictionfromwhichnoappealcanbeoristaken, such provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. (d) transfer to Xencor all of Aimmune's right, title and interest in and to any and all regulatory filings, Regulatory Approvals and other Regulatory Materials for the Product; 41

11.5 Insurance. Aimmune shall procure and maintain insurance, including clinical trials insurance and product liability insurance, adequate to cover its obligations hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which the Product is being clinically tested in human subjects or commercially distributed or sold by Aimmune pursuant to this Agreement; provided, that any such clinical trials insurance coverage shall, prior to the First Commercial Sale of a Product, in no event be less than [***] Dollars ($[***]) per loss occurrence, and product liability insurance coverage shall, after such First Commercial Sale, in no event be less than [***] Dollars ($[***]) per loss occurrence. It is understood that such insurance shall not be construed to create a limit of Aimmune's liability with respect to its indemnification obligations under this ARTICLE 11. Aimmuneshallprovidexencorwithwrittenevidenceofsuchinsurancepriortocommencementofthisagreementanduponexpirationofanyonecoverage. Aimmune shall provide Xencor with written notice at least Holdings [***] ([***]) days prior to the cancellation, nonrenewal or material change in such insurance or self-insurance which materially adversely affects the rights of Xencor hereunder. ARTICLE 7 Payment Holdingss21

Name: Jayson Dallas, M.D Name Holdings: Bassil Dahiyat, Ph.D. 10.3 Additional Representations, Warranties and Covenants of Aimmune. Aimmune hereby represents, warrants and covenants to Xencor that, as of the Effective Date:

7.1 Upfront Payments. Within [***] ([***]) days after the effective date of this agreement, aimmune shall issue to xencor shares of aimmune common stock (the "shares") in accordance with that certain stock issuance agreement, dated the date hereof, by and among xencor and aimmune (the "stock issuance agreement"), and pay to xencor by wire transfer of immediately available funds holdings, into an account designated in writing by xencor, an amount equal to five million dollars ($5,000,000) (together with the issuance of the shares, the "upfront payment"). TheUpfrontPaymentshallbenonrefundableandnoncreditableagainstanyotherpaymentsduehereunder. 14.1.1 all rights and licenses granted to aimmune hereunder shall immediately terminate and be of no further force and effect and aimmune shall cease developing commercializing manufacturing and packaging and labeling such product in and for all applicable countries; provided, that Aimmune and its Affiliates will be entitled, during the period 40

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

LaurenBarbiero (646) 564-2156 lbarbiero@w2ogroup.com

ARTICLE 5 COMMERCIALIZATION

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

10.6.1 Compliance with Anti-Corruption Laws. In connection with this Agreement, each Party represents, warrants and covenants to the other PartythatithascompliedandwillcomplywithallApplicableLaws (including Anti-Corruption Laws) and industry codes dealing with government procurement, conflicts of interest, corruption or bribery, including, if applicable, the U.S. Foreign corrupt practices act of 1977 as amended and any laws enacted to implement the organization of economic cooperation and development convention on combating bribery of foreign officials in international business transactions. 11.2 IndemnificationbyAimmune. Aimmune hereby agrees to save, indemnify, defend and hold Xencor, its Affiliates, and their respective directors, agents and employees harmless from and against any and all Losses arising in connection with any and all Claims resulting or otherwise arising from (i) any breach by Aimmuneofanyofitsrepresentations, warranties, covenants or obligations pursuant to this Agreement, (ii) [***], (iii) the negligence or willful misconduct by Aimmune (or its Affiliates, Sublicensees, subcontractors, wholesalers or distributors) or their respective officers, directors, employees, agents or consultants in performing any obligations under this Agreement, or (iv) the Development, Manufacturing, PackagingandLabelingorCommercializationoftheAntibodyoraProducthereunderduringoraftertheTerm (including, for clarity, any product liability Losses resulting therefrom) by Aimmune (or its Affiliates, Sublicensees, subcontractors, wholesalers or distributors) or their respective officers, directors, employees, agents or consultants, in each case except to the extent that such LossesaresubjecttoindemnificationbyXencorpursuanttoSection11.1. 10.3.1 [***]

4.2 No Other Regulatory Filings. ExceptasotherwiseexpresslysetforthinthisARTICLE4, Aimmune and Aimmune Agreement Entities shall not file any Regulatory Materials or Regulatory Approvals that are based on any Xencor Technology. ARTICLE 2 Licenses 13

(b) Third Party Intellectual Property. Aimmune shall have the right (but not the obligation), at its own expense (subject to the reduction provided for by this Section 7.3.2(b)), to obtain any licenses from any Third Parties that are not Sublicensees of Aimmune with respect to a Product in such country under any issued Patents that would be infringed by the practice of Xencor Technology licensed under Section  Holdings2.1 with respect to a given Product in a particular country (each such Patent, a "Third Party Patent"). If aimmune obtains such a license to a third party patent aimmune shall be entitled to credit [***] percent ([***]%) of the royalties paid to such third party during a calendar quarter against the royalty payment otherwise payable by aimmune to xencor pursuant to this section  holdings7.3 with respect to such product and such country in such calendar quarter. Notwithstanding the foregoing, AimmuneshallhavenorighttoreducepaymentsduetoXencorunderthisAgreementbyanyamountpaidto [***] in connection with the Upstream Agreement or any other agreement entered into between Aimmune and [***]. This press release concerns PALFORZIA (AR101), which has been approved for marketing by the FDA in the United States and has not been approved for marketing by the EMA or Swissmedic. AR101 in Europe is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated. "Aimmune's focus, clinical success and regulatory expertise in food allergy demonstrate their capability to advance AIMab7195 with highly complementary CODIT pipeline programs to create new options for people living with food allergy," said Bassil Dahiyat, Ph.D., President and CEO of Xencor. "aimab7195 is designed to reduce levels of ige a key mediator of allergic response and there is strong scientific rationale that this reduction would synergize with the activity of desensitization therapies."

source: aimmune therapeutics inc. 8-k 2/5/2020

1.68 "royalty term holdings" means with respect to a product on a country holdings-by-country basis the period of time beginning on the firstcommercialsaleofsuchproductinsuchcountry and ending the later of (i) the expiration of the last to expire valid claim covering the antibody or product in such country or (ii) [***] ([***]) years from the first commercial sale of such product in such country. Notwithstanding subsections (i) and (ii) above, the Royalty Term for a Product in a country shall not [***]. Source: aimmune therapeutics inc. 8-k 2/5/2020

1.20 "commercialize" means with respect to the product to promote market distribute sell (and offer for sale or contract to sell) import export or otherwise commercially exploit or provide product support for the product and to conduct activities other than development or manufacturing in preparation for conducting the foregoing activities including activities to produce commercialization support data and to secure and maintain market access and reimbursement. "Commercializing" and "Commercialization" shall have correlative meanings. For the avoidance of doubt, commercializationdoesnotincludedevelopmentandmanufacturing. 3

(ii) The Party not pursuing the suit, action or proceeding hereunder will provide reasonable assistance to the other Party, including by providing access to relevant documents and other evidence and making its employees available, subject to the other Party's reimbursement of any costs incurred by the non-enforcing or defending Party in providing such assistance Holdings. Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the PrivateSecuritiesLitigationReformActof1995. Because such statements are subject to risks and uncertainties Holdings, actual results may differ materially from those expressed or implied by such forward-looking statements. Suchstatementsinclude, but are not limited to, statements regarding: aimmune's expectations regarding the potential benefits of aimab7195; and Aimmune's expectations regarding potential applications of the CODIT™  approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the expectation that aimmune will need additional funds to finance its operations; Aimmune's dependence on the success of PALFORZIA; Aimmune's reliance on third parties for the manufacture of AIMab7195, PALFORZIA and other product candidates; possible regulatory developments in the United States and foreign countries; And aimmune's ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune's most recent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2019. All forward holdings-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. 9.6 Patent Marking. AimmuneshallmarktheProductmarketedandsoldbyAimmune (or the other Aimmune Agreement Entities) hereunder with appropriate patent numbers or indicia. Article 9 intellectual property matters 26

1.22 "control" or "controlled by" means, with respect to any know-how, invention, patent, technology, copyright, trademark or other intellectual property right, possession by a party or its affiliates holdings (whether by ownership, license grant or other means) of the legal right to grant the right to access or use, or to grant a license or a sublicense to, such know-how, invention, patent, technology, copyright, trademark or other intellectual property right as provided for herein without violating the proprietary rights of any third party or any terms of any agreement or other arrangement between such party holdings (or any of its affiliates) and any third party. 10.5 NoOtherRepresentationsorWarranties. Except as expressly stated in this agreement no representations or warranties whatsoever whether express or implied including warranties of merchantability fitness for a particular purpose non-infringement or non-misappropriation of third party intellectual property rights are made or given by or on behalf of a party. Except as expressly stated in this agreement, all representations and warranties, whetherarisingbyoperationoflaworotherwise, are hereby expressly excluded. Xencor inc. 12.4 Publications. Except for disclosures permitted under this agreement holdings if xencor its affiliates or its employee(s) or consultant(s) wishes to make a publication or presentation specific to the product or which otherwise may reasonably contain know-how or other intellectual property of aimmune xencor must receive written approval not to be unreasonably withheld conditioned or delayed from aimmune at least [***] ([***]) days prior to submission for publication or presentation. If Aimmune, its Affiliates, or its employee(s) or consultant(s) wishes to make a publication specific to the Product or which otherwise may reasonably contain Xencor Technology Holdings, Aimmune shall deliver to Xencor a copy of the proposed written publication or an outline of an oral disclosure at least [***] ([***]) days prior to submission for publication or presentation and reasonably consider any comments of Xencor thereon; provided that subject to Sections 12.1 through 12.3, to the extent such publication describes or is specific to Xencor Technology, Aimmune must receive written approval, not to be unreasonably withheld, conditioned or delayed, from Xencor prior to submitting such publication to any Third Party. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

portions of the proposed filing a reasonable time prior to the filing thereof), and shall use reasonable efforts where practicable to consider such comments to the extent consistent with such Party's disclosure obligations under applicable securities laws or rules of a securities exchange. License development and commercialization agreement

10.3.2 aimmune and its affiliates (a) have not developed or commercialized and (b) are not developing or commercializing either directly or through enabling any third party any antibody [***] other than the antibody and product pursuant to this agreement holdings. Brisbane holdings calif. - February 5, 2020 - Aimmune Therapeutics, Inc. (nasdaq: aimt), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it has obtained an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody xmab®7195 from xencor, inc. Aggregate Annual Net Sales Royalty Rate [***] [***]% [***] [***]% [***] [***]% [***] [***]% [***] [***]%

Omitted pursuant to Regulation S-K, Item 601(a)(5) 54

(d) payments made as part of a Co-pay Program for a Product; and

4.3 PharmacovigilanceandMedicalInquiries. 1.24 "designatedofficer" means, with respect to xencor, the chief executive officer of xencor (or its designee), and, with respect to aimmune, the chiefexecutiveofficerofaimmune (or its designee). 10.1 mutual representations and warranties holdings. Each Party hereby represents and warrants to the other Party as follows, as of the Effective Date:

1.28 "E.U. Major Countries" means the United Kingdom, France, Germany, Italy, and Spain. AIMMUNE Holdings THERAPEUTICS Holdings, INC. 1.71 "Third Party" means any Person other than Xencor Holdings, Aimmune or their respective Affiliates. Omitted pursuant to Regulation S Holdings-K, Item 601(a)(5) 50

Omitted pursuant to Regulation S-K, Item 601(a)(5) 55

1.54 "Phase I Clinical Trial" means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 CFR §312.21(a) or comparable regulations in any country or jurisdiction outside the U.S., and any amended or successor regulations. 9.3.3 Cooperation. The Parties agree to cooperate in the preparation, filing, prosecution and maintenance of all Patents under this Section  Holdings9.3, including obtaining and executing necessary powers of attorney and assignments by the named inventors, providing relevant technical reports to the filing PartyconcerningtheInventiondisclosedinsuchPatent, obtaining execution of such other documents which are needed in the filing and prosecution of such Patent, and, as requested by a Party, updating each other regarding the status of such Patent, and shall cooperate with the other Party so far as reasonably necessary with respect to furnishing all information and data in its possession reasonably necessary to obtain or maintain such Patents. As used herein, "Confidential Information" means all Know-How and other information and materials received by either Party from the other Party or its Affiliates pursuant to this Agreement. The foregoing obligations and the other obligations set forth in this Section 12.1 shall not apply with respect to any portion of such Confidential Information which:

10.2.11 Neither Xencor nor its Affiliates or, to the knowledge of Xencor, its licensees, sublicensees or subcontractors have made any material misstatements in any regulatory filing with any Regulatory Authority with respect to the Antibody or Product. 1.73 "upstream agreement" means that certain [***] agreement by and between xencor and the [***] dated [***]. 11

article 5 commercialization 19

source: aimmune therapeutics inc. 8-k 2/5/2020

1.81 "xencor product specific patent" means (i) the patents identified on schedule 1.81 including patents issuing from any patent application set forth on schedule 1.81 (ii) with respect to all patents set forth on schedule 1.81 all provisional applications substitutions continuations continuations- in-part divisionals renewals patents-of-addition reissues reexaminations and extensions (iii) any [***] and (iv) all international and domestic counterparts of any of the foregoing. Omitted pursuant to Regulation S-K, Item 601(a)(5) 51

15.12 Interpretation. Except where the context expressly requires otherwise Holdings, (a) the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words "include", "includes" and "including" shall be deemed to be followed by the phrase "without limitation", (c) the word "will" shall be construed to have the same meaning and effect as the 46

1.55 "Phase II Clinical Trial" means a study in humans for which a primary endpoint is a preliminary determination of efficacy in patients with the disease being studied, as more fully defined in 21 CFR §312.21(b) or comparable regulations in any country or jurisdiction outside the U.S., and any amended or successor regulations. Phase II Clinical Trial shall include in all cases any phase I/II clinical trial. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

in patients. AIMab7195 is designed to clear IgE rapidly from circulation, to prevent the production of IgEbypreventingtheactivationofIgE-positive B cells, and to block IgE from interacting with its receptor on immune cells. AIMab7195 has been evaluated in two Phase 1 studies that enrolled more than 100 healthy volunteers and patients with allergy and atopic disease. Article 15 miscellaneous43

source: aimmune therapeutics, inc., 8-k, 2/5/2020

source: aimmune therapeutics, inc., 8-k, 2/5/2020

aimmune licenses exclusive worldwide rights to xencor's xmab®7195 for the developmentofnext-generation food allergy treatments

(a) no valid claim. On a country Holdings-by-country and Product-by-Product basis, if at any time during the Royalty Term with respect to such country and such Product, such Product is not Covered by any Valid Claim of a [***], the royalty rate applied to Net Sales of such Product shall be the royalty rate in Section 7.3.1 reduced by [***] percent ([***]%) for so long as during the Royalty Term such Product is not Covered by a Valid Claim of a [***] in such country. 5.4.1 Product Trademark. Aimmune shall commercialize the product under the trademark and the trade dress selected by aimmune (the "product trademark" and the "product trade dress", respectively). 1.63 "promotional materials holdings" means all written printed video or graphic advertising promotional educational and communication materials (other than the product labels and package inserts) for marketing advertising and promoting of the product for use (i) by a sales representative or a medical science liaison or (ii) in advertisements web sites or direct mail pieces. 10

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

5.4.3 MaintenanceofProductTrademark. During the term aimmune or the other aimmune agreement entities will use commercially reasonable efforts to establish and maintain the product trademark and will [***]. 8.3 Taxes. 1.44 "Know-How" means all technical, scientific, regulatory and other information, results, knowledge, techniques and data, in whatever form and whether or not confidential, patented or patentable, including Inventions, invention disclosures, discoveries, plans, processes, practices, methods, knowledge, trade secrets, know-how, instructions, skill, experience, ideas, concepts, data (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, safety, quality control, and preclinical and clinical data), formulae, formulations, compositions, specifications, marketing, pricing, distribution, cost, sales and manufacturing data or descriptions. Know-How does not include any Patent claiming any of the foregoing. Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 15 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAbantibodyengineeringtechnologyenablessmallchangestothestructureofmonoclonalantibodiesresultinginnewmechanismsoftherapeuticaction. For more information, please visit www.xencor.com. Xencor® and XmAb® are registered trademarks of Xencor, Inc. About aimab7195 (formerly xmab®7195)

source: aimmune therapeutics, inc., 8-k, 2/5/2020

media contact jason i. Spark canale communications 619-849-6005 jason@canalecomm.com

14.5 accrued rights. Expiration or termination this agreement for any reason will be without prejudice to any rights that will have accrued to the benefit of a party prior to the effective date of such expiration or termination. Such expiration or termination will not relieve a Party from obligations that are expressly indicated to survive the expiration or termination of this Agreement. 42

1.34 "GoodClinicalPractices" or "GCP" means all applicable Good Clinical Practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials, including, as applicable, (i) as set forth in the International Conference on Harmonisation of Technical Requirements for Registration of 5

ARTICLE 14 Effects of Expiration Or Termination 40

4.3.4 Recall, Withdrawal, or Market Notification of Product. In the event that any Governmental Authority threatens or initiates any action to remove the Product from the market, Aimmune shall notify Xencor of such communication promptly, but in no event later than [***] ([***]) Business Days, after receipt thereof. Aimmune shall [***] any recall, withdrawal or market notification of the Product. As between the Parties, all costs and expenses associated with implementing a recall, withdrawal or market notification with respect to the Productshallbeborneby [***]. About  HoldingsAIMab7195 (formerly XmAb®7195)

1.16 "Calendar Year" means the period beginning on the 1st of January and ending on the 31st of December of the same year; provided, however, that (a) the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the same year and (b) the last Calendar Year of the Term shall commence on January 1 of the Calendar Year in which this Agreement terminates or expires and end on the date of termination or expiration of this Agreement Holdings. Aimab7195 is an anti-ige monoclonal antibody with enhanced binding to the fc gamma receptor iib (fcyriib). IgE recognizes and interacts with allergens and, as a result, can activate immune cells, such as mast cells and basophils, that drive an allergic response in patients. AIMab7195 is designed to clear IgE rapidly from circulation, to prevent the production of IgE by preventing the activation of IgE-positive B cells, and to block IgE from interacting with its receptor on immune cells. AIMab7195 has been evaluated in two Phase 1 studies that enrolled more than 100 healthy volunteers and patients with allergy and atopic disease. As used in this agreement, the following initially capitalized terms shall have the meanings set forth in this article 1 or as otherwise defined elsewhere in this agreement:

12.1.3 except as set forth above, each party agrees that it shall provide or permit access to confidential information of the other party only to holdings (i) the receiving party's attorneys, independent accountants and financial advisors for the sole purpose of enabling such attorneys, independent accountants and financial advisors to provide advice to the receiving party and (ii) the receiving party's affiliates, directors, officers, employees, consultants, advisors, actual or potential acquirers and permitted subcontractors, sublicensees and subdistributors, and to the directors, officers, employees, consultants, advisors and permitted subcontractors, actual or potential acquirers, sublicensees and subdistributors of such affiliates, who have a need to know such confidential information to assist the receiving party with the 37

source: aimmune therapeutics, inc., 8-k, 2/5/2020

10.2.6 otherthanassetforthinschedule10.2.6, [***] the issued patents within the xencor patents are neither invalid nor unenforceable. Source: aimmune therapeutics, inc., 8-k, 2/5/2020

article 3 development

source: aimmune therapeutics, inc., 8-k, 2/5/2020

1.56 "phase iii clinical trial" means a controlled study in humans that is performed after preliminary evidence suggesting effectiveness of a product has been obtained, and is intended to demonstrate or confirm the therapeutic benefit of such product and to gather the additional information about effectiveness and safety that is needed to evaluate the overall 9

5.4.4 noinclusionofxencorlogosonpackagingandpromotionalmaterials. Notwithstanding anything to the contrary herein, Aimmune shall not use any Xencor trademark, names, logos or housemark in connection with any Promotional Materials or the Product without Xencor Holdings's written consent. Without limiting the foregoing, aimmune will take no action that will interfere with or diminish xencor's rights in its respective trademarks, names and logos, and if xencorreasonablybelievesthattheuseofanytrademarks, names and logos by aimmune hereunder is interfering with or diminishing its rights, xencor shall notify aimmune thereof in writing and aimmune shall promptly cease use of such trademarks, names or logos in such manner. 10.2.14 to xencor's knowledge xencor has disclosed to aimmune all material information in its possession or control relating to the antibody and product and all such information is accurate in all material respects. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

Contacts

Charles Liles 626-737-8118 cliles@xencor.com

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

1.8 "Aimmune Patent" means any Patent that (i) (a) is Controlled by Aimmune Holdings (or its Affiliates) as of the Effective Date or comes under the Control of Aimmune (or its Affiliates) during the Term (other than as a result of the licenses granted by Xencor to Aimmune under this Agreement) and (b) that would be infringed by the Development, Manufacture, Commercialization or use of the Antibody or Product or that claims or Covers Aimmune Know-How, or (ii) is an Aimmune Collaboration Patent. Under the terms of the agreement, aimmune will make an upfront payment to xencor of $5 million in cash and $5 million in equity, equivalent to 156,238 newly issued shares of aimmune common stock at $32.0025/share, the seven-day volume weighted average price. Xencor also is eligible to receive up to $385 million based on the achievement of certain clinical development, regulatory and commercialization milestones - beginning with the initiation of a Phase 2 clinical trial - and is eligible to receive a high single-digit to mid-teen percentage of royalties upon commercialization of AIMab7195. Aimmune will be solely responsible for costs related to the development of aimab7195 and plans to provide a development plan in the coming months. Forward-Looking Statements

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

1.80 "Xencor Patent Holdings" means Xencor General Patents and Xencor Product Specific Patents. 1.39 "ifrs" means international financial reporting standards or with respect to the u.s. as appropriate generally accepted accounting principles in the u.s. (gaap) in each case consistently applied. Forward-lookingstatements

1.26 "development activities" means those development activities undertaken by or on behalf of aimmune with respect to the product. 10.1.4 All Consents and Approvals Obtained Holdings. Except with respect to Regulatory Approvals for the Development, ManufacturingorCommercializationoftheProductorasotherwisedescribedinthisAgreement, (i) all necessary consents, approvals and authorizations of, and (ii) all notices to, and filings by such Party with, all Governmental Authorities and other Persons required to be obtained or provided by such Party as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained and provided Holdings, except for those approvals, if any, not required at the time of execution of this Agreement. 31

ARTICLE 9 INTELLECTUAL PROPERTY MATTERS

(c) normal and customary trade, cash and quantity discounts, allowances and credits actually allowed or paid; 1Section 94.9 "Active Ingredient Holdings" means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure or function of the body. (i) if the cumulative net sales of such product in such country during such calendar quarter are equal to or less than [***] percent ([***]%), but are greater than [***] percent ([***]%), of the baseline quarter net sales, then the royalty rate will be reduced for such calendar quarter by [***] percent ([***]%); and

Develop, Manufacture, or Commercialize the Product for use outside the Licensed Field. Furthermore holdings xencor hereby covenants and agrees that it shall not (and shall cause its affiliates not to) either directly or through granting a license or other right to or otherwise facilitating a third party to (a) develop manufacture or commercialize the antibody or the product during the term (b) commence any [***] of any [***] that is not the antibody or a product and that holdings [***] for use in the licensed field prior to the [***] ([***]t h) anniversary of the effective date or (c) develop manufacture or commercialize any [***] that is not the antibody or a product and that [***] for use in the aimmune field during the term. It is the desire and intent of the Parties that the restrictive covenants contained in this Section 2.4 be enforced to the fullest extent permissible under Applicable Laws Holdings and public policies applied in each jurisdiction in which enforcement is sought. Xencor and Aimmune believe that the restrictive covenants in this Section 2.4 are valid and enforceable. However, if any restrictive covenant should for any reason become or be declared by a competent court or competition authority to be invalid or unenforceable in any jurisdiction, such restrictive covenant shall be deemed to have been amended to the extent necessary in order that such provision be valid and enforceable, such amendment shall apply only with respect to the operation of such provision of this Section 2.4 in the particular jurisdiction in which such declaration is made. Further, both Parties agree that [***] of this Agreement. Article 14 effects of expiration or termination

10.2.9 the upstream agreement is in full force and effect and, to its knowledge, no facts or circumstances exist that would give either party to the upstream agreement the right to terminate for the other party's material breach thereof. 1.29 "FDA" means the United States Food and Drug Administration and any successor Regulatory Authority having substantially the same function. 1.19 "Combination Product" means any Product containing an Active Ingredient that is not an Antibody. Such combination product shall be either (a) priced and sold in a single package containing such multiple products or (b) packaged separately but sold together for a single price. 10.1.3 No Conflicts Holdings. The execution, delivery and performance of this Agreement by it does not (i) conflict with any agreement, instrument or understanding, oral or written, to which it is a party and by which it may be bound or (ii) violate any Applicable Law. (b) governmental and other rebates (or equivalents thereof) granted to managed health care organizations, pharmacy benefit managers (or equivalents thereof), federal, state, provincial, local and other governments, their agencies and purchasers and reimbursers or to trade customers; 5.4 Product Trademarks and Product Trade Dress. 1.83 Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement:

XmAb7195, which has been renamed AIMab7195, was originally developed by Xencor for the treatment of allergic asthma. It uses three distinct mechanisms of action to reduce blood serum IgE and suppress IgE-producing cells. Aimmune initially plans to develop AIMab7195 as an adjunctive treatment with select Characterized Oral Desensitized ImmunoTherapy (CODIT™) programs, including PALFORZIA™ , to explore treatment outcomes in patients with food allergies. 1.27 "Dollar" or "$" means the legal tender of the UnitedStatesofAmerica. 1.46 "Major Territory Holdings" means the [***]. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

9.3.1 Xencor General Patents. Subject to, and without limiting Aimmune's rights under, Section 9.4 of this Agreement, Xencor shall have the sole right to prepare, file, prosecute and maintain all Xencor General Patents, [***], including by conducting reissues, reexaminations, interferences, and/or defending against post grant proceedings, such as inter partes reviews and oppositions and other challenges to the validity or enforceability of such Xencor General Patents. Xencor shall keep Aimmune generally informed of the status of Xencor General Patents upon Aimmune's request reasonable request from time-to-time. Xencor® and XmAb® are registered trademarks of Xencor, Inc. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

1.15 "Calendar Quarter" means each three (3) month period commencing January 1, April 1, July 1 or October  Holdings1 of any year; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first full Calendar Quarter thereafter, and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement. 1.69 "Sales Representative" means an individual who is employed by a Party and who performs details and other promotional efforts with respect to the Product. 1.42 "invention" means any discovery or invention, whether or not patentable, conceived or otherwise made by either party, or by both parties, in exercising its rights or performing its obligations under this agreement. For clarity, either Party may disclose without any limitation such Party Holdings's U.S. federal income tax treatment and the U.S. Federal income tax structure of the transactions relating to such party that are based on or derived from this agreement as well as all materials of any kind (including opinions other tax analyses or a complete copy of this agreement and any amendments thereto) relating to such tax treatment or tax structure except to the extent that nondisclosure of such matters is reasonably necessary in order to comply with applicable securities laws. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

(iii) As between the Parties, Xencor will have the sole right (but not the obligation) to take the appropriate steps to enforce any Patent within the Xencor General Patents against infringement by a Third Party Holdings, that is, in each cause, conducting the manufacture, sale, use, offer for sale or import of any biopharmaceutical product. Xencor may take steps including the initiation, prosecution and control of any suit, proceeding or other legal action by counsel of its own choice and shall bear the costs of such enforcement, as applicable. 29

schedule 1.81 xencor product specific patent holdingss 52

4.3.3 regulatory authority communications. In addition to its obligations under this Agreement, each PartyshalldisclosetotheotherParty (and each PartyshallhavetherighttosubsequentlydisclosetoitsAffiliatesandsubcontractorsandlicensees, specifically those licensees of the Product in the case of Aimmune, who are bound by obligations of confidentiality substantially consistent with those in ARTICLE 12) the following regulatory information: All material information pertaining to material adverse or potentially material adverse actions taken or that may be taken by Regulatory Authorities, in connection with the Product or Antibody, including any notice, audit notice, notice of initiation by Regulatory Authorities of investigations, detentions, seizures or injunctions concerning the Product or Antibody, notice of violation letter (i.e., an untitled letter), warning letter, service of process or other equivalent 18

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

1.49 "Medical Science Liaison" means an individual who is employed by or on behalf of Aimmune or its Affiliates and who provides educational services and other educational efforts directed towards the medical and/or scientific community. 7

1.6 "Aimmune Invention Holdings" means an Invention that is Invented, solely or jointly with a Third Party Holdings, by or on behalf of AimmuneoritsAffiliates. 8.5 LatePayments. In the event that any payment due under this agreement is not sent to xencor when due in accordance with the applicable provisions of sections 7.1, 7.2, or 8.1, the payment shall accrue interest from the date due at the [***], plus an additional [***] 25

term section "agreement" preamble "bankrupt party" 14.7 "breachingparty" 13.2 [***] 1.73 "claim" 11.1 "cmc" 1.66 "commercializationdata" 5.5 "confidential information holdings" 12.1.1 "controlling party" 9.4.1(a) "court" 15.13.3 "dispute" 15.1 "effective date" preamble "ich" 1.34

article 10 representations, warranties and covenants. COMPLIANCE

Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of applicable securities laws, including, but not limited to, the quotations from the chief executive officers of XencorandAimmuneandanyexpectationsrelatingtothepotentialbenefitsofAIMab7195; its clinical development, synergies with CODIT™  programs and efficacy; Regulatory approval. or commercialization. Such statements involve known and unknown risks uncertainties and other factors that may cause actual results performance or achievements and the timing of events to be materially different from those implied by such statements and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2018 as well as Xencor's subsequent filings with the Securities and Exchange Commission. All forward-looking statements are based on Xencor's current information and belief as well as assumptions made by Xencor. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. This caution is made under the safe harbor provisions of the private securities litigation reform act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law. Net sales shall not include sales to affiliates sublicenseesorcontractorsengagedbyaimmunetodevelop manufacture or commercialize the product solely to the extent that such affiliate sublicensees or contractor purchasing the product resells such product to a third party. However, subsequent sales of Product by such Aimmune Affiliates, Sublicensees or contractors to a Third Party shall be included in the Net Sales when sold in the market for end-user use. (c) is subsequently disclosed to the receiving Party or any of its Affiliates by a Third Party that is lawfully in possession thereof without obligation to keep it confidential; Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

9.3.2 Xencor Product Specific Patent, Aimmune Patents and Joint Collaboration Patents Holdings. arbitration or litigation. Toaccomplishthisobjective, the Parties agree to follow the procedures set forth in this Section 15.1 if and when a Dispute arises under this Agreement. IfthePartiesareunabletoresolveanyDisputewithin [***] ([***]) days after such Dispute is submitted to it Holdings, either Party may, by written notice to the other Party, have such Dispute referred to Designated Officers of each Party for attempted resolution. In the event the Designated Officers or their delegates are not able to resolve such Dispute within such [***] ([***]) day period after receipt of written notice, then each Party is free to pursue any remedy at law or in equity available to such Party consistent with Section 15.13. Schedule 6.1 Initial Product Supply

1.82 "XencorTechnology" means Xencor Know-How and Xencor Patents. 12

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

1.25 "Develop" means to research, develop, analyze, test and conduct preclinical trials, ClinicalTrials (including, for the avoidance of doubt, Phase IV Clinical Trials and any preclinical/clinical/CMC commitments following Regulatory Approval Holdings) and all other regulatory trials, for the Product, as well as any and all activities pertaining to manufacturing development, formulation development, medical affairs and lifecycle management, including new indications, new formulations and all other activities, including regulatory activities, related to securing and maintaining Regulatory Approval for the Product Holdings, or otherwise characterizing or understanding the properties and uses of the Antibody or the Product. "Developing Holdings" and "Development" shall have correlative meanings. 4

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020 1.30 "FD&C Act" means the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder. 12.2 Publicity. Promptly after the effective date, the parties shall each issue the applicable press release in the form attached hereto as schedule 12.2, with respect to this agreement. Subject to the foregoing, any press releases or other public statements or disclosures regarding the subject matter of this agreement shall be subject to the express prior written consent of each of the parties. provided that a disclosure shall be permitted without the other Party's consent to the extent that it does not contain information beyond that included in a prior disclosure approved in writing by both Parties. NotwithstandingtheforegoinganydisclosurewhichisrequiredbyApplicableLawortherulesoftheU.S. Securities and exchange commission or any securities exchange, as reasonably advised by the disclosing party's counsel, may be made without the prior consent of the other party, although, prior to any such legally required disclosure by a party, such party shall use reasonable efforts where practicable to give the other party reasonable notice and an opportunity to comment on the proposed disclosure. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

1Section 34.9 "AimmuneCommonStock" means Aimmune's common stock, par value $0.0001 per share. 5.3 reports. Without limiting Aimmune's other reporting obligations hereunder, Aimmune shall, during the fourth Calendar Quarter of each Calendar Year after the First Commercial Sale of a Product, provide Xencor [***] involving Product during the preceding four (4) Calendar Quarters. Omitted pursuant to Regulation S-K, Item 601(a)(5) 53

1.33 "Generic Product" means, with respect to a Product and on a country-by-country basis, a product that (a) is marketed for sale in such country [***], (b) contains or comprises an antibody with the [***], (c) is approved [***], and (d) such product, as and to the extent required, is approved through an abbreviated process based in reliance, at least in part, on the safety and efficacy data generated for the prior Regulatory Approval of such Product by Aimmune or an Aimmune Agreement Entity in such country Holdings (similar, with respect to the United States, to an Abbreviated New Drug Applications under Section 505(j) of the FD&C Act (21 USC355(j))) or is approved as a "Biosimilar Biologic Product" under TitleVII, Subtitle A Biologics Price Competition and Innovation Act of 2009, Section 42 U.S.C. 262 section 351 of the phsa or outside the united states in accordance with european directive 2001/83/ec on the community code for medicinal products (article 10(4) and section 4 part ii of annex i) and european regulation eec/2309/93 establishing the community procedures for the authorization and evaluation of medicinal products each as amended and together with all associated guidance and any counterparts thereof or equivalent process inside or outside of the united states or eu to the foregoing. 2.2.3 Upstream Agreement. Aimmune acknowledges, understands and agrees that (i) the xencor know-how licensed to aimmune pursuant to section 2.1 includes certain know-how licensed to xencor pursuant to the upstream agreement, (ii) the license to such xencor know-howconstitutesasublicenseundertheupstreamagreement, (iii) aimmune's rights to such xencor know-how are subject and subordinate to the terms and conditions of the upstream agreement, (iv) aimmunewillcomplywiththeupstreamagreement, including undertaking such activities as xencor reasonably requests to so comply holdings, (v) [***] is responsible for any and all payments due under the upstream agreement (following the effective date) in connection with developing, manufacturing and commercializing the product by or on behalf of aimmune (including by or on behalf of its affiliates or sublicensees), and (vi) aimmune received a copy of the upstream agreement prior to the effective date. 4.1.4 Reporting and Review. Pursuant to the updates to be provided to Xencor under Section 2.5, Aimmune shall keep Xencor reasonably informed in connection with the preparation of all material Regulatory Materials Holdings, Regulatory Authority review of Regulatory Materials, and Regulatory Approvals, in each case with respect to the Product. 17

by: /s/ jayson dallas, m.d by: /s/ bassil dahiyat holdings, ph.d. 2.5 Progress Updates. Aimmune shall keep Holdings Xencor informed as to its progress and activities relating to the Development, Manufacture and Commercialization of the Product Holdings on [***] basis (i.e., every [***] ([***]) months), including by providing updates on the status of studies necessary for obtaining Regulatory Approval with respect to the Product, regulatory matters and meetings with RegulatoryAuthoritieswithrespecttotheProduct, and Commercialization activities commencing no later than [***] ([***]) year prior to the date on which Aimmune estimates the First Commercial Sale of Product will occur. Additionally, to the extent applicable, such updates shall include summaries of aimmune's development plans for the product for the ensuing holdings [***] ([***]) year time period. Any information disclosed under this Section 2.5 shall be treated as Confidential Information as defined in Section  Holdings12.1. 14.4 DispositionofCommercializationRelatedMaterials. Upon the termination of this Agreement, Aimmune will promptly deliver to Xencor in electronic, sortable form (a) a list identifying all wholesalers and other distributors involved in the Commercialization of the Product, will reasonably consider providing customer lists (e.g., purchasers), where permitted under Applicable Law and under applicable agreements with Third Parties, at Xencor's expense, related to the Commercialization of the Product, and (b) all Promotional Materials as well as any items bearing the Product Trademark or Product Trade Dress and/or any trademarks or housemarks otherwise associated with the Product or Xencor. (ii) if the cumulative Net Sales of such Product in such country during such Calendar Quarter are less than [***] percent ([***]%) of the Baseline Quarter Net Sales of the Baseline Quarter Net Sales, then the royalty rate for such Calendar Quarter will be reduced by [***] percent ([***]%). 8.1 royalty payments and reports. The royalty payments due by aimmune to xencor under section 7.3 shall be calculated reported and paid for each calendar quarter within [***] ([***]) days after the end of each calendar quarter and shall be accompanied by a report setting forth net sales of products by aimmune in sufficient detail to permit confirmation of the accuracy of the royalty payment made including the gross sales and net sales of each product on a country-by-country basis and the exchange rates used in accordance with section 8.2. Without limiting the generality of the foregoing, Aimmune shall require its Affiliates and other Aimmune Agreement Entities to account for its Net Sales and to provide such reports with respect thereto as if such sales were made by Aimmune. 4.3.1 Pharmacovigilance. Subject to Section 4.1.1, Aimmune, as the holder of the Product Approvals, shall be responsible for the collection, review, assessment, tracking and filing of information related to adverse events associated with the Product (whether or not Product Approval has been achieved), in each case in accordance with ApplicableLawandthisAgreement (and Aimmune shall, in the Development and Commercialization of the Product Holdings, record, investigate, summarize, notify, report and review all adverse events in accordance with Applicable Law). 11.3.3 The Indemnifying Party shall keep the Indemnified Party advised of the status of such Claim and the defense thereof and shall consider recommendations made by the Indemnified Party with respect thereto. 35

specified on Schedule 6.1 within [***] ([***]) BusinessDaysfromtheEffectiveDateorotherwiseasagreedtobytheParties, and shall provide appropriate documentation at such time (i.e., appropriate certificates of analysis or compliance, as applicable). The Product shall be made available to Aimmune [***]. For clarity, AimmuneshallbearallcostsinconnectionwithsuchsupplyofProductrelatedtoshipping, taxes, additional testing and other matters. (d) has been published by a Third Party or otherwise enters the public domain through no fault of the receiving Party or any of its Affiliates in breach of this Agreement; or

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

1.40 "IND" means an investigational new drug application, clinical trial authorization or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. 6

ARTICLE 10 Representations, Warranties and Covenants; Compliance 31

10.1.1 Corporate Existence and Power. Itisacompanyorcorporationdulyorganized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the right to grant the licenses granted by it hereunder. 1.66 "regulatory data" means any and all research data pharmacology data chemistry manufacturing and control data preclinical data clinical data and all other documentation submitted or required to be submitted to regulatory authorities in association with regulatory filings for the product (including any applicable drug master files chemistry holdings manufacturing and control holdings ("cmc") data or similar documentation). Schedule  holdings1section 20section 72.40 antibody 50

source: aimmune therapeutics inc. 8-k 2/5/2020

with copies to (which shall not constitute notice): latham&watkinsllp140 scott drive menlo park ca 94025 attention: patrick pohlen judith hasko holdings

1.76 "xencor [***]" means a [***]. 9.2 Disclosures; Disputes Holdings Regarding Inventions. Each Party shall, before filing a new Patent application (including provisionals and continuations-in-part) claiming an Invention, promptly disclose such Invention to the other Party and shall provide to the other Party with a copy of the proposed patent application at least Holdings [***] ([***]) BusinessDaysbeforefilingsuchapplicationorsuchshortertimeasmayberequiredtopreservePatentrights, including the avoidance of a statutory bar or prior publication. IfsuchotherPartybelievesthatthefirstParty's proposed Patent application discloses such other Party's Confidential Information, such other Party shall so notify the first Party within such [***] ([***]) Business Days after receipt thereof, and such first Party shall amend its proposed application to comply with the confidentiality provisions of this Agreement. If the Parties are in agreement as to the designation of the Invention as a Xencor Invention, Joint Invention or Aimmune Invention, as applicable, they can 26

10.6.2 Prohibited Conduct Holdings. In connection with this Agreement, each Party represents, warrants and covenants to the other Party that it has not made, offered, given, promised to give, or authorized, and will not make, offer, give, promise to give, or authorize, any bribe, kickback, payment or transfer of anything of value, directly or indirectly, to any person or to any Government Official for the purpose of: (i) improperly influencing any act or decision of the person or Government Official; (ii) inducing the person or government official to do or omit to do an act in violation of a lawful or otherwise required duty. (iii) securing any improper advantage; Or (iv) inducing the person or government official to improperly influence the act or decision of any organization including any government or government instrumentality in order to assist such party in obtaining or retaining business. ARTICLE 6 SUPPLY

(a) Aimmune, itself or with or through its Affiliates and Sublicensees, shall (i) use CommerciallyReasonableEffortstoCommercializetheProductintheLicensedFieldthroughouttheMajorTerritory, (ii) represent the Product accurately and fairly, and (iii) not sell or distribute the Product in a bundle with other products at a discount that is not equitably allocated between Product and other products with which the Product is bundled. [***]. 22

1.64 "Regulatory Approval" means, with respect to any biopharmaceutical product in any regulatory jurisdiction for a given indication, approval from the applicable Regulatory Authority permitting the manufacture, sale, distribution or Commercialization of such biopharmaceutical product in such regulatory jurisdiction for such indication in accordance with Applicable Law, including any Pricing Approvals. (e) transfer to Xencor all of Aimmune's right, title and interest in and to any and all Development-related data and Commercialization Data Controlled by Aimmune for the Product; And

term section "party" or "parties" preamble "producttradedress" 5.4.1 "product trademark holdings" 5.4.1 "recovery" 9.4.2(c)(iv) "shares holdings" 7.1 "stock issuance agreement" 7.1 "sublicensee" 2.3.2 "term" 13.1 "third party patent" 7.3.2(b) "upfront payment" 7.1 "vat" 8.3.3

15.6 assignment. NeitherPartymayassignortransferthisAgreementoranyrightsorobligationshereunderwithoutthepriorwrittenconsentoftheotherParty, except that a Party may make such an assignment or transfer without the other Party's written consent to (a) any of its Affiliates, in whole or in part, or (b) any Third Party in connection with (i) the acquisition of such Party by or merger or consolidation of such Party with another entity or (ii) a merger, consolidation, sale of stock, sale of all or substantially all of such Party's assets or other similar transaction in which such Third Party either becomes the owner of all or substantially all of the business and assets of (y) such Party or (z) that portion of such Party's business or business unit relating to this Agreement. Any permitted successor or assignee of rights or obligations hereunder shall in a writing delivered to the other party expressly assume the performance of such rights or obligations. Except as set forth in the immediately preceding sentence in the event of an assignment or transfer as permitted above in this section 15.6 the assigning or transferring party shall remain responsible (jointly and severally) with such affiliate for the 45

with copies to (which shall not constitute notice): xencor inc. 111 West Lemon Avenue Monrovia, CA 91016 Attention: Chief Executive Officer

8.3.4 [***]. NO W THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:

About Xencor Holdings, Inc. For Net Sales of a Combination Product, the NetSalesapplicabletosuchCombinationProductinacountrywillbedeterminedbymultiplyingthetotalNetSalesofsuchcombinedproductbythefractionA/(A+B), where A is the actual price of the Product that is included in such Combination Product in the same dosage amount or quantities in the applicable country during the applicable quarter if sold separately Holdings, and B is the sum of the actual prices of all other products with which such Product is combined in such Combination Product, in the same dosage amount or quantities in the applicable country during the applicable quarter if sold separately. If A or B cannot be determined because values for such Product or such other products with which such Product is combined are not available separately in a particular country, then the Parties shall discuss an appropriate allocation for the fair market value of such Product and such other products with which such Product is combined to mutually determine Net Sales for the relevant transactions based on an equitable method of determining the same that takes into account Holdings, in the applicable territory, the relative contribution of each Active Ingredient, variations in dosage formulation and relative value to the end user of each Active Ingredient. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

(a) credits or allowances actually granted for damaged Product, returns or rejections of Product, price adjustments and billing errors; 1.51 "Patents" means any and all (i) issued patents, (ii) pending patent applications, including all provisional applications, substitutions, continuations, continuations-in-part, divisionals and renewals, and all patents granted thereon, (iii) patents-of-addition, reissues, and reexaminations, including patent term adjustments, Patent Term Extensions, supplementary protection certificates or the equivalent thereof, (iv) inventor's certificates, (v) other forms of government-issued rights substantially similar to any of the foregoing, and (vi) United States and foreign counterparts of any of the foregoing. Article 11 indemnification

9.3 patentfilings prosecution and maintenance. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

11.3 Indemnification Procedures Holdings. Source: aimmune therapeutics, inc., 8-k, 2/5/2020

1.23 "cover" or "covering" means, with respect to a particular subject matter at issue and a relevant patent, that the manufacture, use, sale, offer for sale or importation of such subject matter would, but for the existence of this agreement, infringe one or more claims in such patents (or in the case of a patent application, would infringe if such application were to issue). 2.1 Grant to Aimmune. Subject to the terms and conditions of this Agreement, XencorherebygrantstoAimmuneduringtheTermanexclusive, worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive, payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2, solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall retain the right under and with respect to Xencor Patents and Xencor Holdings's interest in Joint Collaboration Patents to the extent necessary to perform its obligations under this Agreement Holdings. 1.47 "Manufacture" or "Manufacturing" or "Manufactured" means, with respect to the Antibody and Product, the receipt, handling and storage of Active Ingredients, drug substance or drug product, medical devices and other materials, the manufacturing, processing, PackagingandLabeling, holding (including storage), quality assurance and quality control testing (including release) of the Antibody and Product (other than quality assurance and quality control related to development of the manufacturing process, which activities shall be considered Development Activities) and shipping of the Antibody and Product. 15.3 Force Majeure. No Party shall be liable for any failure to perform Holdings, or be considered in breach of, its obligations under this Agreement (other than obligations to make payments of money) to the extent such performance has been delayed, interfered with or prevented by an event of Force Majeure, and the obligations of such Party under this Agreement (other than obligations to make payments of money) whose performance is affected by ForceMajeureshallbesuspendedduring, but not longer than, the continuance of the event of Force Majeure. Any Party that experiences an event of Force Majeure shall provide prompt notice of such event to the other Party, including and an estimate of the likely period of time during which its performance will be affected, and shall use reasonable efforts to remove the condition constituting Force Majeure. In the event of a prolonged condition of Force Majeure that makes it unreasonable to continue to perform other activities then being performed by the Parties and their Affiliates pursuant to this Agreement Holdings, the Parties shall consult directly as to whether they should appropriately scale back their respective activities in order to avoid waste or inappropriate usage of resources under the circumstances. 10.2.10 xencor has not used in any capacity in connection with its development or manufacture of the product prior to the effective date any person who has been debarred pursuant to section 306 of the fd&c act (or similar applicable law outside of the u.s.) or who is the subject of a conviction described in such section. 32

11.4 Limitation of Liability. Neither party shall be liable to the other party for any lost profits oranyspecial consequential incidental or indirect damages arising from or relating to any breach of this agreement regardless of any notice of the possibility of such damages. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION  Holdings11.1 or 11.2, OR DAMAGES AVAILABLE FOR A PARTY'S BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 12. (iv) Any settlements, damages or other monetary awards (a "Recovery") recovered pursuant to a suit, action or proceeding brought pursuant to Section 9.4.2(b) will be allocated first to the costs and expenses of the Party taking such action, and second, to the costs and expenses (if any) of the other Party, with any remaining amounts (if any) to be allocated as follows: (i) for a suit, action or proceeding controlled by Aimmune, Aimmune retains [***] percent ([***]%) and Xencor retains Holdings [***] percent ([***]%) of such Recovery, and (ii) for a suit, action or proceeding controlled by Xencor, be allocated between the Parties such that Xencor retains [***] percent ([***]%) and Aimmune retains [***] percent ([***]%) of such Recovery, provided that, notwithstanding the foregoing clauses (i) or (ii), the portion of any Recoveriesfromanysuchactionsinvolving [***]. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

9.4 InfringementofThirdPartyPatents; Enforcement of Patents. 2.3.1 performance by affiliates. The Parties recognize that each may perform some or all of its obligations under this Agreement through Affiliates Holdings; provided, however, that each Party shall remain responsible for and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Each Party hereby expressly waives any requirement that the other Party exhausts any right, power or remedy, or proceed against an Affiliate, for any obligation or performance hereunder prior to proceeding directly against such Party. Wherever in this Agreement the Parties delegate responsibility to Affiliates, the Parties agree that such entities may not make decisions inconsistent with this Agreement, amend the terms of this Agreement or act contrary to its terms in any way. 13.4 Termination by Aimmune. Aimmune may terminate this Agreement in its entirety at any time for its convenience upon sixty Holdings (60) days' prior written notice to Xencor. 10.2.12 Neither Xencor nor, to the knowledge of Xencor, its Affiliates, licensees, sublicensees or independent contractors have received any notices or claims of noncompliance with Applicable Law relating to activities conducted by or facilities used by, Xencor, its Affiliates, licensees, sublicensees or independent contractors in connection with the Development or Manufacture of Antibody or Product, and Xencor is not aware of any reasonable basis for any such notices or claims. (b) Aimmune shall not (i) [***], or (ii) utilize deceptive, misleading or unethical business practices, in each case in the course of performing activities pursuant to this Agreement. 5.1 Commercialization. During the Term, as between the Parties, Aimmune shall be solely responsible for Commercializing the Product. Aimmune shall be responsible for one hundred percent Holdings (100%) of the expenses (including Pre-Marketing and other Commercialization expenses) incurred in connection with the Commercialization of the Product. 2.6 Upstream Agreement. During the Term Holdings, neither Xencor nor any of its Affiliates shall (a) encumber any GPExTechnology, as defined in the Upstream Agreement, to the extent included within the Xencor Technology, or commit any act or permit the occurrence of any omission that would cause the breach or termination of the Upstream Agreement, or otherwise knowingly take actions or permit omissions that would adversely affect the rights granted to Aimmune hereunder with respect to the Xencor Patents and Xencor Know-How, or (b) without Aimmune's prior written consent, amend or otherwise modify or permit to be amended or modified, the Upstream Agreement in any respect that would adversely affect Aimmune's rights with respect to, the AntibodyorProducts. Xencor shall promptly notify Aimmune upon Xencor's becoming aware of any alleged, threatened, or actual breach of the Upstream Agreement by either Party and shall not take any action that would reasonably give rise to the right of the counterparty to terminate the Upstream Agreement. 1.10 "antibody" means xencor's humanized antibody known as xmab7195 having the sequence listed in schedule 1.10. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

word "shall", (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person shall be construed to include the person's successors and assigns, (f) the words "herein", "hereof" and "hereunder", and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof Holdings, (g) all references herein to Articles, Sections, Exhibits or Schedules shall be construed to refer to Articles, Sections, Exhibits or Schedules of this Agreement Holdings, and references to this Agreement include all Exhibits and Schedules hereto, (h) the word "notice" means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party or the Parties hereunder to "agree", "consent" or "approve" or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term "or" shall be interpreted in the inclusive sense commonly associated with the term "and/or."

1.59 "Pricing Approval" means, with respect to any country where a Governmental Authority authorizes reimbursement or access, or approves or determines pricing, for biopharmaceutical products, receipt (or, if required to make such authorization, approval of determination effective publication) of such reimbursement or access authorization or pricing approval or determination (as the case may be). (i) as between the parties, aimmune will have the first right (but not the obligation) to take the appropriate steps to enforce any patent within the xencor product specific patents holdings, aimmune patents and joint collaboration patents against infringement by a third party, that is, in each cause, conducting the manufacture, sale, use, offer for sale or import of any biopharmaceutical product. Aimmune may take any steps it reasonably believes appropriate to enforce such Patent Holdings, including the initiation, prosecution and control of any suit, proceeding or other legal action by counsel of its own choice and shall bear the costs of such enforcement, as applicable. Notwithstanding the foregoing, Xencor will have the right, at [***] expense, to be represented in any such action by counsel of its own choice. 3.4 Records, Reports and Information. Aimmune shall, and shall cause each of the other aimmuneagreemententitiesto, maintain current and accurate records of all development activities conducted by it and all data and other information resulting from such work (which records shall include, as applicable, books, records, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs and documentation thereof (e.g., samples of materials and other graphic or written data generated in connection with the development activities)). Such records shall properly reflect all work done and results achieved in the performance of the Development Activities in sufficient detail and in good scientific manner appropriate for regulatory and patent purposes Holdings. Aimmune shall document all preclinical studies and Clinical Trials to be conducted in formal written study reports according to applicable national and international (e.g., ICH, GCP and GLP) guidelines. Article 3 development16

7.3.2 royalty reductions. 10.2.4 Schedule 1.79 and Schedule 1.81, when taken together, set forth a true, complete and correct list of all Patents Controlled by Xencor or its Affiliates as of the Effective Date that relate to the Antibody or Product and are necessary for Developing, Manufacturing or Commercializing the Antibody or Product. 8.2 Manner and Place of Payment. Whenconversionofpaymentsfromanycurrencyotherthanu.s. Dollars is required Holdings, such conversion shall be at an exchange rate equal to the rates of exchange for the currency of the country from which such payments are payable as published by The Wall Street Journal, Western U.S. Edition, on the last business day of the calendar quarter in which the applicable sales were made in such country. All payments hereunder shall be payable in U.S. Dollars. All payments owed under this agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by xencor unless otherwise specified in writing by xencor. Article 12 confidentiality

(e) sales taxes, vat taxes and other taxes directly linked to the sales of product holdings; IntheeventthatProductissoldaspartofafinancialbundlewithotherproductsorincludedinfinancialpackagedealstocustomersandinsuchcase, the price of Product relevant for the calculation of Net Sales will be the average invoiced sales price of Product in the preceding Calendar Quarter sold separately less the average discount of all products sold as part of such bundle or package. 8

12.5 UseofNames. Except as otherwise set forth in this agreement neither party shall use the name of the other party in relation to this transaction in any public announcement press release or other public document without the written consent of such other party which consent shall not be unreasonably withheld; provided, however, that subject to Section 12.3, either Party may use the name of the other Party in any document filed with any Regulatory Authority or Governmental Authority Holdings, including the SecuritiesandExchangeCommissionortherulesofanysecuritiesexchange. 2.2 Additional Licensing Provisions. 1.35 "good laboratory practices" or "glp" means all applicable good laboratory practice standards including as applicable (i) as set forth in the then-current good laboratory practice standards promulgated or endorsed by the fda as defined in 21 c.f.r. Part 58, and (ii) the equivalent Applicable Law in any relevant country, each as may be amended and applicable from time to time. About Aimmune

Contacts: Investors: DeDe Sheel (917) 834-1494 dsheel@aimmune.com

15.13 Governing Law Holdings and Equitable Relief Holdings. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020

12.1 Confidential Information. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020